Abstract:Background & Aims New antiviral approaches are urgently required that target multiple aspects of the hepatitis B virus (HBV) replication cycle to improve rates of functional cure. HBV RNA represents a novel therapeutic target. Here, we programmed Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas13b endonuclease, to specifically target the HBV pregenomic RNA (pgRNA) and viral mRNAs in a novel approach to reduce HBV replication and protein expression. Methods Cas13b CRISPR RNAs (crRNAs) were designed to target multiple regions of HBV pgRNA. Mammalian cells with replication competent wildtype HBV DNA of different genotypes, a HBV stable cell line, a HBV infection model and a hepatitis B surface antigen (HBsAg)-expressing stable cell line were transfected with Psp Cas13b-blue fluorescent protein (BFP) and crRNAs plasmids and the impact on HBV replication and protein expression was measured. WT HBV DNA, Psp Cas13b-BFP and crRNA plasmids were simultaneously hydrodynamically injected into mice, and sera HBsAg was measured. Psp Cas13b mRNA and crRNA were also delivered by lipid nanoparticles (LNP) in a HBsAg-expressing stable cell line and the impact on secreted HBsAg determined. Results Our HBV targeting crRNAs strongly suppressed HBV replication and protein expression in mammalian cells by up to 96% (p<0.0001). HBV protein expression was also reduced in an HBV stable cell line and in the HBV infection model. CRISPR-Cas13b crRNAs reduced HBsAg expression by 50% (p<0.0001) in vivo . LNP-encapsulated Psp Cas13b mRNA reduced secreted HBsAg by 87% (p=0.0168) in a HBsAg-expressing stable cell line. Conclusions Together, these results show that CRISPR-Cas13b can be programmed to specifically target and degrade HBV RNAs to reduce HBV replication and protein expression, demonstrating its potential as a novel therapeutic option for chronic HBV infection. Impact and implications There is an urgent need for new treatments that target multiple aspects of the HBV replication cycle. Here, we present CRISPR-Cas13b as a novel strategy to target HBV replication and protein expression paving the way for its development as a potential new treatment option for patients living with chronic hepatitis B.

Peroxisome Proliferator-Activated Receptor Alpha Antagonism Inhibits Hepatitis C Virus Replication

Inhibition of Hepatitis B Virus Replication by Targeting Ribonucleotide Reductase M2 Protein.

Direct Imaging of the Disruption of Hepatitis C Virus Replication Complexes by Inhibitors of Lipid Metabolism

Activation of the Liver X Receptor Pathway Inhibits HBV Replication in Primary Human Hepatocytes

Restriction of hepatitis B virus replication by c-Abl-induced proteasomal degradation of the viral polymerase.

Identification of Retinoic Acid Receptor Agonists as Potent Hepatitis B Virus Inhibitors via a Drug Repurposing Screen

PAPD5/7 Are Host Factors That Are Required for Hepatitis B Virus RNA Stabilization

Hydrogen Peroxide Inhibits Hepatitis C Virus Replication by Downregulating Hepatitis C Virus Core Levels through E6-Associated Protein-Mediated Proteasomal Degradation

Poly(rC)-Binding Protein 1 Limits Hepatitis C Virus Virion Assembly and Secretion

Protocatechuic acid inhibits hepatitis B virus replication by activating ERK1/2 pathway and down-regulating HNF4α and HNF1α in vitro

Psoralen inhibits hepatitis B viral replication by down-regulating the host transcriptional machinery of viral promoters

The retinoic acid receptor (RAR) α-specific agonist Am80 (tamibarotene) and other RAR agonists potently inhibit hepatitis B virus transcription from cccDNA

PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice

PRMT5 Restricts Hepatitis B Virus Replication Through Epigenetic Repression of Covalently Closed Circular DNA Transcription and Interference with Pregenomic RNA Encapsidation

Hepatitis C virus core protein inhibits hepatitis B virus replication by downregulating HBx levels via Siah-1-mediated proteasomal degradation during coinfection

CRISPR-Cas13b-mediated suppression of hepatitis B virus replication and protein expression

The aryl hydrocarbon receptor–cytochrome P450 1A1 pathway controls lipid accumulation and enhances the permissiveness for hepatitis C virus assembly

HBx-Derived Constrained Peptides Inhibit the Secretion of Hepatitis B Virus Antigens

Regulation of Hepatitis B Virus Replication by Modulating Endoplasmic Reticulum Stress (ER-Stress)

Prospero-Related Homeobox Protein (prox1) Inhibits Hepatitis B Virus Replication Through Repressing Multiple Cis Regulatory Elements

Inhibitors of Endoplasmic Reticulum Α-Glucosidases Potently Suppress Hepatitis C Virus Virion Assembly and Release